

Financial Tear Sheet

Corporate Profile

Proteon Therapeutics is working to deliver a new future for patients and families affected by kidney and vascular diseases, where innovation drives health improvement and healthcare professionals have the tools they need to improve patient outcomes. Proteon is a late-stage biopharmaceutical company developing potentially transformative treatment options to address some of the most urgent needs in chronic kidney disease (CKD) and peripheral artery disease (PAD) with the goal of redefining how these diseases are treated. Proteon's lead product candidate, vonapanitase, is a first-in-class recombinant human elastase designed to treat vessel injury that leads to blood vessel blockage and reduced blood flow. Proteon is evaluating vonapanitase in a Phase 3 trial in patients with CKD undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis and in a Phase 1 program in patients suffering from PAD.

IR Contact

George Eldridge
 781-890-0102 x1026
investor@proteontherapeutics.com

Media Contact

Ann Stanesa
 Ten Bridge Communications
 617-230-0347
proteon@tenbridgecommunications.com

Stock Information

PRTO (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price **\$2.25**

Change (%) ▲ 0.05 (2.27%)

Volume 27,071

52 Week Low \$1.10

Market Cap \$39,643,691

Rolling EPS -1.56

PE Ratio 0

Shares Outstanding 17,619,418

Data as of 10/13/17 4:00 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed. View [Attributions and Sources](#)

Recent Press Releases & Upcoming Events

	Date	Title
09/05/17 Proteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017	11/09/17	CIDA on Controversies in Dialysis Access Location San Diego, CA
08/07/17 Proteon Therapeutics Announces Second Quarter 2017 Financial Results	11/18/17	44th Annual VEITH Symposium Location New York, NY
08/02/17 Proteon Therapeutics Announces Closing of \$22 Million Convertible Preferred Stock Financing		

SEC Filings

Filing Date	Form
09/18/17	4
08/22/17	SC 13D/A
08/22/17	8-K
08/21/17	EFFECT

Corporate Governance

Timothy P. Noyes	President and Chief Executive Officer
Steven K. Burke, M.D.	Senior Vice President and Chief Medical Officer
George A. Eldridge	Senior Vice President and Chief Financial Officer
Daniel P. Gottlieb	Vice President, Corporate Development
Scott Toner	Senior Vice President, Marketing
Pamela Gustafson	Vice President, Clinical Research
Matthew Kowalsky	Vice President, Legal
John Najim	Vice President, Manufacturing and Process Development
Marco Wong, M.D., Ph.D.	Medical Director
John Najim	Vice President, Manufacturing and Process Development

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.